Evaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings

Evaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings: A double-blind randomized and placebo controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200408046988N1

Enrollment

Registered

2020-04-29

Start date

2020-04-14

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Intervention group: Melatonin 3 mg tablets will be given every eight hours for all patients undergoing standard treatment for Qovid 19 (Hydroxychloroquine 200 tablets every 12 hours).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Consent to participate in the study Confirmed and suspicious COVID-19 patients Not participating in another clinical trial plan simultaneously

Exclusion criteria

Exclusion criteria: Lack of consent for the study Changing the other routine medications during the project

Design outcomes

Primary

Measure	Time frame
Confirmed and possible Coronavirus 2019. Timepoint: at the time of admission. Method of measurement: CT scan - PCR test Corona virus.	—

Secondary

Measure	Time frame
Laboratory study. Timepoint: daily. Method of measurement: CBC diff-ABG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNajmeh Davoodian

Gonabad University of Medical Sciences

najmeh.davoudian@gmail.com+98 51 5723 6828

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026